Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

Published:2019-10 Issue:10 Volume:20 Page:1360-1369
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Giuliano Mario,Schettini Francesco,Rognoni Carla,Milani Manuela,Jerusalem Guy,Bachelot Thomas,De Laurentiis Michelino,Thomas Guglielmo,De Placido Pietro,Arpino Grazia,De Placido Sabino,Cristofanilli Massimo,Giordano Antonio,Puglisi Fabio,Pistilli Barbara,Prat Aleix,Del Mastro Lucia,Venturini Sergio,Generali Daniele

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology

Reference38 articles.

1. Extending survival with chemotherapy in metastatic breast cancer;O'Shaughnessy;Oncologist,2005

2. Clinical implications of the intrinsic molecular subtypes of breast cancer;Prat;Breast,2015

3. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study;Gong;Sci Rep,2017

4. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer;Baselga;N Engl J Med,2012

5. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-09-12

2. Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions;Frontiers in Pharmacology;2024-09-06

3. The choice of optimal therapy for ER+ HER2-metastatic breast cancer (PROMETHEUS): all-Russian analysis of physicians’ preferences – updated survey results;Medical alphabet;2024-09-05

4. PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer;2024-08-07

5. The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study;BMC Cancer;2024-07-30